Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fluid-electrolyte homeostasis requires histone deacetylase function
Kelly A. Hyndman, Joshua S. Speed, Luciano D. Mendoza, John M. Allan, Jackson Colson, Randee Sedaka, Chunhua Jin, Hyun Jun Jung, Samir El-Dahr, David M. Pollock, Jennifer S. Pollock
Kelly A. Hyndman, Joshua S. Speed, Luciano D. Mendoza, John M. Allan, Jackson Colson, Randee Sedaka, Chunhua Jin, Hyun Jun Jung, Samir El-Dahr, David M. Pollock, Jennifer S. Pollock
View: Text | PDF
Research Article Cell biology Nephrology

Fluid-electrolyte homeostasis requires histone deacetylase function

  • Text
  • PDF
Abstract

Histone deacetylase (HDAC) enzymes regulate transcription through epigenetic modification of chromatin structure, but their specific functions in the kidney remain elusive. We discovered that the human kidney expresses class I HDACs. Kidney medulla-specific inhibition of class I HDACs in the rat during high-salt feeding results in hypertension, polyuria, hypokalemia, and nitric oxide deficiency. Three new inducible murine models were used to determine that HDAC1 and HDAC2 in the kidney epithelium are necessary for maintaining epithelial integrity and maintaining fluid-electrolyte balance during increased dietary sodium intake. Moreover, single-nucleus RNA-sequencing determined that epithelial HDAC1 and HDAC2 are necessary for expression of many sodium or water transporters and channels. In performing a systematic review and meta-analysis of serious adverse events associated with clinical HDAC inhibitor use, we found that HDAC inhibitors increased the odds ratio of experiencing fluid-electrolyte disorders, such as hypokalemia. This study provides insight on the mechanisms of potential serious adverse events with HDAC inhibitors, which may be fatal to critically ill patients. In conclusion, kidney tubular HDACs provide a link between the environment, such as consumption of high-salt diets, and regulation of homeostatic mechanisms to remain in fluid-electrolyte balance.

Authors

Kelly A. Hyndman, Joshua S. Speed, Luciano D. Mendoza, John M. Allan, Jackson Colson, Randee Sedaka, Chunhua Jin, Hyun Jun Jung, Samir El-Dahr, David M. Pollock, Jennifer S. Pollock

×

Figure 2

Metabolic cage results from rats on a 2- or 7-day HSD with intramedullary infusion of MS275 (gray) or vehicle (white).

Options: View larger image (or click on image) Download as PowerPoint
Metabolic cage results from rats on a 2- or 7-day HSD with intramedullar...
Box plots with median and maximum and minimum values plotted. (A) MS275 treatment does not significantly affect sodium intake but (B) leads to increased consumption of water and (C) subsequent increase in urine production after 7 days, compared with vehicle-infused rats. (D) Urine osmolality and (E) urinary urea concentration were reduced with MS275 treatment. Two-factor ANOVA reported and *P < 0.05 compared with vehicle from post hoc Holm-Šidák multiple comparison test reported. (F) Free water clearance (CH2O) shows production of a dilute urine; however, it is significantly different with MS275 treatment. Unpaired, 2-tailed Student’s t test reported. (G and H) IM expression of AQP2 and the inhibitory phosphorylation site of AQP2 S261 after 7 days of vehicle or MS275 infusion. (G) MS275 treatment results in a significant reduction in AQP2 expression and (H) a significant increase in phosphorylation of S261. Unpaired, 2-tailed Student’s t test reported. Intramedullary infusion of the class I HDAC inhibitor MS275 results in reduced NO. (I) Urinary NOx (nitrite + nitrate) excretion fails to increase in MS275-infused rats that were eating a 2- and 7-day HSD. Two-factor ANOVA and *P < 0.05 compared with vehicle HSD2 from post hoc Holm-Šidák multiple comparison test reported. (J) Urinary NOx excretion is significantly decreased with MS275 treatment in rats drinking 1% NaCl. There was a decrease after 2 days of MS275 treatment. *P < 0.05 from vehicle day 7 as determined by paired, 2-tailed Student’s t test. (K) IM NOS expression in rats on a high-salt chow. Seven days of MS275 treatment results in a significant decrease in NOS1α, NOS1β, and NOS3 protein abundance. NOS2 expression was not statistically significant from vehicle-treated rats. n = 4 for vehicle, 5 for MS275. Unpaired, 2-tailed Student’s t test reported. DxT, interaction between drug and time.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts